XOMA (XOMA)
(Delayed Data from NSDQ)
$25.34 USD
-1.16 (-4.38%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $25.22 -0.12 (-0.47%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
XOMA 25.34 -1.16(-4.38%)
Will XOMA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for XOMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XOMA
Xoma (XOMA) Moves 7.7% Higher: Will This Strength Last?
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
XOMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Vertex (VRTX): Can Its 5.0% Jump Turn into More Strength?
Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates
Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates
Other News for XOMA
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
Xoma acquires economic interest in three assets from Dare Bioscience
Dare Bioscience secures $22M in non-dilutive strategic royalty financing
Xoma initiated with bullish view at Leerink, here's why
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)